D. W. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
D. W. Jones has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
M. Winter
6 shared publicationsM. J. Gallimore
Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, and
5 shared publicationsI. J. Mackie
Haemostasis Research Unit, Haematology Department, University College, London, UK
2 shared publicationsS. L. Harris
Kent Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, and
2 shared publicationsG. Evans
1 shared publicationH.P. Wendel
1 shared publication
Latest Publications
- 1 July 2007
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 5
HUMAN VASCULAR ENDOTHELIAL CELLS INFLUENCE THE WHOLE BLOOD THROMBIN GENERATION ASSAY
- 1 July 2007
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 5
HUMAN VASCULAR ENDOTHELIAL CELLS INFLUENCE THE WHOLE BLOOD THROMBIN GENERATION ASSAY
- Open Access
- 1 May 2001
- Published by Wiley in British Journal of Haematology
- Vol. 113 (2) , 550-552
Antibodies to factor XII and recurrent fetal loss in patients with the anti‐phospholipid syndrome
Forty female patients with either primary anti‐phospholipid syndrome (n = 26) or systemic lupus erythematosus (anti‐phospholipid syndrome positive) (n = 14) were investigated for levels of factor XII, the presence of lupus anticoagulant and antibodies to cardiolipin, beta 2‐glycoprotein I and factor XII. Twenty‐one patients had a history of recurrent fetal loss (> 2, mean = 2·6). Lupus anticoagulant positivity showed a weak association with recurrent fetal loss (odds ratio = 1·1). While there was no association between the presence of antibodies to cardiolipin or beta 2‐glycoprotein I with recurrent fetal loss, antibodies to factor XII showed a strong and statistically significant association (odds ratio = 5·4, P = 0·025).
- 1 May 2001
- Published by Wiley in British Journal of Haematology
- Vol. 113 (2) , 550-552
Open AccessAntibodies to factor XII and recurrent fetal loss in patients with the anti‐phospholipid syndrome
Forty female patients with either primary anti‐phospholipid syndrome (n = 26) or systemic lupus erythematosus (anti‐phospholipid syndrome positive) (n = 14) were investigated for levels of factor XII, the presence of lupus anticoagulant and antibodies to cardiolipin, beta 2‐glycoprotein I and factor XII. Twenty‐one patients had a history of recurrent fetal loss (> 2, mean = 2·6). Lupus anticoagulant positivity showed a weak association with recurrent fetal loss (odds ratio = 1·1). While there was no association between the presence of antibodies to cardiolipin or beta 2‐glycoprotein I with recurrent fetal loss, antibodies to factor XII showed a strong and statistically significant association (odds ratio = 5·4, P = 0·025).
- Open Access
- 1 September 2000
- Published by Wiley in British Journal of Haematology
- Vol. 110 (3) , 721-726
Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII
Antibodies to factor XII (FXII) have previously been identified in some patients who were lupus anti‐coagulant‐positive. The relationship between these antibodies and FXII levels appeared to be variable. The aim of the present study was to confirm the presence of antibodies to FXII in patients with well characterized antiphospholipid syndrome (APS) and to establish their potential effect on levels of FXII. Forty‐two patients with APS were studied; 21 patients were found to have either immunoglobulin (Ig)G or IgM antibodies to FXII by enzyme‐linked immunosorbent assay (ELISA) using a highly purified preparation of FXII (> 99% pure). Levels of FXII were statistically significantly lower (P = 0·02) in patients with antibodies to FXII when compared with patients without antibodies to FXII (median = 91 μ/dl, s.d. = 39·1, median = 122 μ/dl, s.d. = 41·1 respectively). Four of the 21 patients with antibodies to FXII were found to have FXII levels below the laboratory normal range. Antibodies to FXII are present in significant numbers of patients with APS and may lead to acquired FXII deficiency.
- 1 September 2000
- Published by Wiley in British Journal of Haematology
- Vol. 110 (3) , 721-726
Open AccessReduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII
Antibodies to factor XII (FXII) have previously been identified in some patients who were lupus anti‐coagulant‐positive. The relationship between these antibodies and FXII levels appeared to be variable. The aim of the present study was to confirm the presence of antibodies to FXII in patients with well characterized antiphospholipid syndrome (APS) and to establish their potential effect on levels of FXII. Forty‐two patients with APS were studied; 21 patients were found to have either immunoglobulin (Ig)G or IgM antibodies to FXII by enzyme‐linked immunosorbent assay (ELISA) using a highly purified preparation of FXII (> 99% pure). Levels of FXII were statistically significantly lower (P = 0·02) in patients with antibodies to FXII when compared with patients without antibodies to FXII (median = 91 μ/dl, s.d. = 39·1, median = 122 μ/dl, s.d. = 41·1 respectively). Four of the 21 patients with antibodies to FXII were found to have FXII levels below the laboratory normal range. Antibodies to FXII are present in significant numbers of patients with APS and may lead to acquired FXII deficiency.
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 81 (03) , 387-390
Antibodies to Factor XII Associated with Lupus Anticoagulant
Summary: Falsely low levels of factor XII (FXII) have been documented in patients who are lupus anticoagulant positive (LA+). In addition, we have previously noted a surprisingly high incidence (20.9%) of apparently true FXII deficiency in patients who were LA+. We have hypothesised that this may be partly due to the presence of antibodies to FXII.The aim of the present study was to investigate whether LA+ patient plasmas contain antibodies directed either against FXII or FXII in association with phospholipids. Plasma samples from 60 blood donors, all LA negative, and 51 LA+ patients were tested using ELISA assays employing purified FXII, phosphatidylserine (PS) and phosphatidylethanolamine (PE). We have identified seven patients whose plasma contained either IgG or IgM that reacted with purified FXII in the absence of PS or PE. When PS was included in the assay system four additional patient plasmas were shown to contain either IgG or IgM that reacted with FXII. The plasma of one patient contained IgG that reacted with FXII both in the presence and absence of PS. There was no reactivity to FXII with either IgG or IgM when PE was included in the assay system. Affinity purified IgG from three patients whose plasma reacted with FXII in the ELISA assay in the absence of PS, gave a positive reaction in an immunoblot assay. These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency.
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 81 (03) , 387-390
Antibodies to Factor XII Associated with Lupus Anticoagulant
Summary: Falsely low levels of factor XII (FXII) have been documented in patients who are lupus anticoagulant positive (LA+). In addition, we have previously noted a surprisingly high incidence (20.9%) of apparently true FXII deficiency in patients who were LA+. We have hypothesised that this may be partly due to the presence of antibodies to FXII.The aim of the present study was to investigate whether LA+ patient plasmas contain antibodies directed either against FXII or FXII in association with phospholipids. Plasma samples from 60 blood donors, all LA negative, and 51 LA+ patients were tested using ELISA assays employing purified FXII, phosphatidylserine (PS) and phosphatidylethanolamine (PE). We have identified seven patients whose plasma contained either IgG or IgM that reacted with purified FXII in the absence of PS or PE. When PS was included in the assay system four additional patient plasmas were shown to contain either IgG or IgM that reacted with FXII. The plasma of one patient contained IgG that reacted with FXII both in the presence and absence of PS. There was no reactivity to FXII with either IgG or IgM when PE was included in the assay system. Affinity purified IgG from three patients whose plasma reacted with FXII in the ELISA assay in the absence of PS, gave a positive reaction in an immunoblot assay. These results suggest that FXII antibodies are present in a significant proportion of LA+ patients and may lead to an erroneous diagnosis of FXII deficiency.
- 1 January 1998
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 9 (2) , 183-188
An automated chromogenic peptide substrate assay for coagulation factor XII
We have developed an automated chromogenic peptide substrate assay for factor XII (FXIIcs) on a Cobas Mira S Plus clinical chemistry analyser using a new commercially available kit. This was used to determine factor XII (FXII) levels in plasma samples from 320 blood donors, 206 patients with a history of venous thrombosis and 74 lupus anticoagulant positive (LA+) patients. Results were compared with those obtained in a clotting assay for FXII (FXIIct) and an immunochemical assay (FXIIag). A satisfactory correlation coefficient of 0.92 and a regression line equation of y = 7.898 + 0.871x was obtained between FXIIcs and FXIIct in the 320 blood donors. Levels of FXII below the calculated normal range were found in nine blood donors (2.8%) and 16 venous thrombosis patients (7.8%). The blood donors and patients with venous thrombosis with low FXIIcs values had FXII levels below our lower limits of normal for both FXIIct and FXIIag; all were lupus anticoagulant negative. When FXII levels were determined in the 74 LA+ patients, 27 (36.5%) gave markedly lower FXII values in the FXIIct when compared with the FXIIcs. FXIIag levels corresponded with FXIIcs. The automated FXIIcs assay is therefore lupus anticoagulant insensitive and allows us to measure FXII levels accurately and routinely in large numbers of patient samples. Blood Coag Fibrinol 9:183–187 × 1998 Lippincott-Raven Publishers.
- 1 January 1998
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 9 (2) , 183-188
An automated chromogenic peptide substrate assay for coagulation factor XII
We have developed an automated chromogenic peptide substrate assay for factor XII (FXIIcs) on a Cobas Mira S Plus clinical chemistry analyser using a new commercially available kit. This was used to determine factor XII (FXII) levels in plasma samples from 320 blood donors, 206 patients with a history of venous thrombosis and 74 lupus anticoagulant positive (LA+) patients. Results were compared with those obtained in a clotting assay for FXII (FXIIct) and an immunochemical assay (FXIIag). A satisfactory correlation coefficient of 0.92 and a regression line equation of y = 7.898 + 0.871x was obtained between FXIIcs and FXIIct in the 320 blood donors. Levels of FXII below the calculated normal range were found in nine blood donors (2.8%) and 16 venous thrombosis patients (7.8%). The blood donors and patients with venous thrombosis with low FXIIcs values had FXII levels below our lower limits of normal for both FXIIct and FXIIag; all were lupus anticoagulant negative. When FXII levels were determined in the 74 LA+ patients, 27 (36.5%) gave markedly lower FXII values in the FXIIct when compared with the FXIIcs. FXIIag levels corresponded with FXIIcs. The automated FXIIcs assay is therefore lupus anticoagulant insensitive and allows us to measure FXII levels accurately and routinely in large numbers of patient samples. Blood Coag Fibrinol 9:183–187 × 1998 Lippincott-Raven Publishers.
- 1 November 1997
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 8 (8) , 531-532
Factor XII determinations and lupus anticoagulants
- 1 November 1997
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 8 (8) , 531-532
Factor XII determinations and lupus anticoagulants